Skip to main content
. 2021 Apr 12;11:7932. doi: 10.1038/s41598-021-86964-y

Table 2.

Carrier frequency of KIR+HLA class I ligand combinations in breast cancer patients and controls.

KIR- HLA combination Healthy controls (n = 278) Breast cancer Comparison
All (n = 162) Advanced (n = 44) Early (n = 70) All versus controls Advanced versus controls
p value OR (95% CI) p value OR (95% CI)
%F (N +) %F (N +) %F (N +)
Inhibitory KIR + HLA class I ligand
2DL1 + C2 +  74.7 (192/256) 67.9 (93/135) 79.5 (31/38) 57.9 (33/56)
2DL2 + 2DL3 + C1 +  34.6 (92/256) 32.7 (50/140) 35.7 (15/38) 29.7 (19/56)
3DL1 + Bw4 +  60.6 (143/233) 50.8 (62/116) 58.8 (20/32) 51.0 (26/48)
3DL2 + A3/A11 +  40.0 (50/125) 42.4 (39/92) 31.8 (7/22) 37.8 (14/37)
Activating KIR + HLA class I ligand
2DS1 + C2 +  26.9 (73/256) 36.1 (53/135) 52.4 (22/38) 21.0 (13/56) 0.001 2.98 (1.54 to 5.79)
3DS1 + Bw4 +  17.7 (46/233) 25.9 (37/116) 29.3 (12/32) 18.6 (11/48) 0.008 2.6 (1.26 to 5.39)
Inhibitory KIR + Activating KIR + HLA class I ligand
2DL1 + C2 + 2DS1 +  26.6 (72/256) 34.5 (51/135) 52.4 (22/38) 19.0 (2/56) 0.001 3.04 (1.56 to 5.89)
2DL1 + C2 + 2DS1 −  45.5 (120/256) 27.8 (42/135) 22.0 (9/38) 32.8 (21/56) 0.0004 0.46 (0.3 to 0.71) 0.005 0.34 (0.15 to 0.73)
3DL1 + Bw4 + 3DS1 +  15.6 (41/233) 20.1 (30/116) 29.3 (12/32) 14.5 (9/48) 0.033 2.23 (1.05 to 4.72)
3DL1 + Bw4 + 3DS1- 40.5 (102/233) 23.7 (32/116) 21.6 (8/32) 28.8 (17/48) 0.001 0.46 (0.28 to 0.73) 0.027 0.41 (0.18 to 0.92)
2DL1 + C2 + 3DL1 + Bw4 + 2DS1 + 3DS1 +  11.5 (30/233) 12.3 (19/116) 19.5 (8/32) 4.6 (3/48)
2DL1 + C2 + 3DL1 + Bw4 + 2DS1 − 3DS1 −  25.9 (66/233) 12.8 (19/116) 12.5 (5/32) 16.1 (10/48) 0.002 0.42 (0.24 to 0.73)